Axa Takes Position in Alkermes Plc (ALKS)

Axa purchased a new position in shares of Alkermes Plc (NASDAQ:ALKS) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 166,926 shares of the company’s stock, valued at approximately $8,487,000. Axa owned approximately 0.11% of Alkermes at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Greenwood Capital Associates LLC lifted its stake in Alkermes by 1.1% in the 2nd quarter. Greenwood Capital Associates LLC now owns 3,770 shares of the company’s stock valued at $219,000 after purchasing an additional 41 shares during the last quarter. M&T Bank Corp lifted its stake in Alkermes by 2.9% in the 2nd quarter. M&T Bank Corp now owns 7,135 shares of the company’s stock valued at $413,000 after purchasing an additional 200 shares during the last quarter. Toronto Dominion Bank lifted its stake in Alkermes by 12.7% in the 2nd quarter. Toronto Dominion Bank now owns 1,875 shares of the company’s stock valued at $109,000 after purchasing an additional 212 shares during the last quarter. Teachers Retirement System of The State of Kentucky lifted its stake in Alkermes by 0.4% in the 2nd quarter. Teachers Retirement System of The State of Kentucky now owns 78,620 shares of the company’s stock valued at $4,558,000 after purchasing an additional 292 shares during the last quarter. Finally, People s United Financial Inc. lifted its stake in Alkermes by 3.3% in the 2nd quarter. People s United Financial Inc. now owns 9,389 shares of the company’s stock valued at $544,000 after purchasing an additional 297 shares during the last quarter. Institutional investors and hedge funds own 99.17% of the company’s stock.

In related news, SVP Laurie Keating sold 6,249 shares of Alkermes stock in a transaction on Wednesday, December 20th. The shares were sold at an average price of $121.20, for a total transaction of $757,378.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP James M. Frates sold 20,932 shares of Alkermes stock in a transaction on Wednesday, November 29th. The stock was sold at an average price of $50.51, for a total transaction of $1,057,275.32. Following the transaction, the senior vice president now directly owns 164,971 shares of the company’s stock, valued at approximately $8,332,685.21. The disclosure for this sale can be found here. Insiders have sold 115,613 shares of company stock valued at $6,112,689 in the last ninety days. Insiders own 5.34% of the company’s stock.

Several brokerages recently commented on ALKS. Credit Suisse Group dropped their price objective on shares of Alkermes from $70.00 to $66.00 and set an “outperform” rating for the company in a research note on Friday, October 27th. Barclays set a $50.00 price objective on shares of Alkermes and gave the company a “hold” rating in a research note on Thursday, October 26th. Citigroup set a $62.00 price objective on shares of Alkermes and gave the company a “hold” rating in a research note on Thursday, October 26th. ValuEngine raised shares of Alkermes from a “sell” rating to a “hold” rating in a research note on Friday, December 1st. Finally, Mizuho set a $81.00 price objective on shares of Alkermes and gave the company a “buy” rating in a research note on Saturday, October 21st. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have issued a buy rating to the company’s stock. Alkermes has a consensus rating of “Hold” and a consensus target price of $63.55.

Alkermes Plc (ALKS) opened at $53.04 on Friday. The stock has a market cap of $8,076.31, a price-to-earnings ratio of -47.78 and a beta of 2.14. Alkermes Plc has a 52 week low of $46.42 and a 52 week high of $63.40. The company has a debt-to-equity ratio of 0.23, a quick ratio of 2.72 and a current ratio of 3.05.

Alkermes (NASDAQ:ALKS) last released its quarterly earnings results on Thursday, October 26th. The company reported $0.03 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.01) by $0.04. The firm had revenue of $217.40 million during the quarter, compared to the consensus estimate of $231.29 million. Alkermes had a negative net margin of 20.12% and a negative return on equity of 7.27%. The company’s revenue for the quarter was up 20.6% on a year-over-year basis. During the same quarter last year, the firm earned ($0.09) earnings per share. sell-side analysts forecast that Alkermes Plc will post -0.59 EPS for the current fiscal year.

WARNING: “Axa Takes Position in Alkermes Plc (ALKS)” was first posted by Community Financial News and is owned by of Community Financial News. If you are reading this piece on another publication, it was copied illegally and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece can be viewed at https://www.com-unik.info/2017/12/23/axa-takes-position-in-alkermes-plc-alks.html.

Alkermes Company Profile

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).

Want to see what other hedge funds are holding ALKS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alkermes Plc (NASDAQ:ALKS).

Institutional Ownership by Quarter for Alkermes (NASDAQ:ALKS)

What are top analysts saying about Alkermes? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Alkermes and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit